Sümeyra Demir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sümeyra Demir has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Damla Ertürk
Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Çukurova University, Adana 01330, Türkiye
2 shared publications - Süheyla Kömür
Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Cukurova University, Adana, Turkiye
2 shared publications - Yeşim Taşova
Cukurova University, Faculty of Medicine
2 shared publications - Adem Kaya
Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Karadeniz Technical University, 61080, Trabzon, Türkiye
1 shared publication - Ahmet Turan Koç
Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Karadeniz Technical University, 61080, Trabzon, Türkiye
1 shared publication - Aslıhan Candevir
Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Çukurova University, Adana, Turkey
1 shared publication
Latest Publications
- Open Access
- 30 May 2026
- Published by Springer Nature in Scientific Reports
Missed opportunities for HIV testing in hospitalised adults in türkiye: ındicator conditions and testing coverage in a national multicentre point-prevalence survey (HIV-ICs-TR)
To quantify the prevalence of HIV testing indications among hospitalised adults in Türkiye, assess HIV testing coverage when clinically indicated, and identify missed diagnostic opportunities in a national multicentre point-prevalence survey. We conducted a national multicentre cross-sectional point-prevalence survey across tertiary referral hospitals from all seven geographical regions of Türkiye. Adult inpatients present at 08:00 on a predefined index day were assessed for predefined HIV testing indications, including AIDS-defining conditions, indicator conditions associated with an expected undiagnosed HIV prevalence ≥ 0.1%, and conditions in which unrecognised HIV could substantially affect clinical management. Among 3,425 hospitalised adults without known HIV infection, 699 (20.4%) had at least one documented HIV testing indication. HIV testing was requested by the primary clinical team in 424/699 patients (60.7%). Testing was lowest in patients with indicator conditions associated with an expected undiagnosed HIV prevalence ≥ 0.1%, and these conditions were independently associated with higher odds of non-performance of HIV testing by the primary clinical team than AIDS-defining conditions (corresponding adjusted odds ratio [aOR] 3.05, 95% confidence interval [CI] 1.67–5.81). In centres with a specialised HIV outpatient clinic, the odds of non-performance of HIV testing by the primary clinical team were independently lower among patients with an appropriate testing indication (corresponding aOR 0.64, 95% CI 0.43–0.95). Following study-team facilitation, overall testing coverage increased to 677/699 (96.9%). Three reactive screening results were identified, including two confirmed new HIV diagnoses. HIV testing indications were common among hospitalised adults in Türkiye, but non-performance of HIV testing by the primary clinical team remained frequent, particularly for non-AIDS indicator conditions. Strengthening indicator-condition-guided testing through structured clinical pathways and institutional HIV expertise may reduce non-performance and support earlier HIV diagnosis.
- 30 May 2026
- Published by Springer Nature in Scientific Reports
Open AccessMissed opportunities for HIV testing in hospitalised adults in türkiye: ındicator conditions and testing coverage in a national multicentre point-prevalence survey (HIV-ICs-TR)
To quantify the prevalence of HIV testing indications among hospitalised adults in Türkiye, assess HIV testing coverage when clinically indicated, and identify missed diagnostic opportunities in a national multicentre point-prevalence survey. We conducted a national multicentre cross-sectional point-prevalence survey across tertiary referral hospitals from all seven geographical regions of Türkiye. Adult inpatients present at 08:00 on a predefined index day were assessed for predefined HIV testing indications, including AIDS-defining conditions, indicator conditions associated with an expected undiagnosed HIV prevalence ≥ 0.1%, and conditions in which unrecognised HIV could substantially affect clinical management. Among 3,425 hospitalised adults without known HIV infection, 699 (20.4%) had at least one documented HIV testing indication. HIV testing was requested by the primary clinical team in 424/699 patients (60.7%). Testing was lowest in patients with indicator conditions associated with an expected undiagnosed HIV prevalence ≥ 0.1%, and these conditions were independently associated with higher odds of non-performance of HIV testing by the primary clinical team than AIDS-defining conditions (corresponding adjusted odds ratio [aOR] 3.05, 95% confidence interval [CI] 1.67–5.81). In centres with a specialised HIV outpatient clinic, the odds of non-performance of HIV testing by the primary clinical team were independently lower among patients with an appropriate testing indication (corresponding aOR 0.64, 95% CI 0.43–0.95). Following study-team facilitation, overall testing coverage increased to 677/699 (96.9%). Three reactive screening results were identified, including two confirmed new HIV diagnoses. HIV testing indications were common among hospitalised adults in Türkiye, but non-performance of HIV testing by the primary clinical team remained frequent, particularly for non-AIDS indicator conditions. Strengthening indicator-condition-guided testing through structured clinical pathways and institutional HIV expertise may reduce non-performance and support earlier HIV diagnosis.
- Open Access
- 26 May 2026
- Published by Doc Design and Informatics Co. Ltd. in Infectious Diseases and Clinical Microbiology
- Vol. 8 (3) , 262-272
Nontuberculosis Mycobacterial Infections: A Series of 14 Cases from a Tertiary Care Center in Türkiye
Objectives: Nontuberculous mycobacteria (NTM) are emerging opportunistic pathogens with an increasing global incidence. However, epidemiological data and treatment outcomes remain limited in Türkiye. This study aimed to evaluate the clinical characteristics, species distribution, and treatment outcomes of NTM infections in a tertiary center in Türkiye. Materials and Methods: A retrospective analysis was conducted of patients diagnosed with NTM infection between 2021 and 2025 in the Department of Infectious Diseases and Clinical Microbiology. The diagnosis was established according to the American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) criteria. Demographic characteristics, risk factors, radiological findings, microbiological profiles, antimicrobial susceptibility patterns, treatment regimens, and clinical outcomes were analyzed. Results: Fourteen patients were included in the study. The mean age was 50.1 ± 13.8 years, and nine patients were male. Underlying risk factors were present in eight patients, including human immunodeficiency virus (HIV) infection (n = 4), malignancy (n = 3), bronchiectasis (n = 1), and chronic obstructive pulmonary disease (COPD) (n = 1). The most frequently identified species were Mycobacterium kansasii (n = 5) and Mycobacterium abscessus (n = 5), followed by Mycobacterium avium, Mycobacterium simiae, Mycobacterium gordonae, and Mycobacterium lentiflavum (n = 1 each). Pulmonary involvement was observed in 10 patients, with nodular lesions in nine and bronchiectasis in five. Among isolates with available antimicrobial susceptibility results (n = 13), susceptibility to clarithromycin, moxifloxacin, linezolid, and amikacin was observed in 12 isolates, whereas resistance was most frequently detected to ciprofloxacin (n = 10) and trimethoprim-sulfamethoxazole (n = 9). Of the 12 patients who initiated treatment, complete clinical response was achieved in nine and partial response in one; two patients with malignancy died before treatment initiation. Conclusion: M. kansasii and M. abscessus were the most frequently identified NTM species in this cohort. Favorable treatment outcomes were observed when therapy was guided by antimicrobial susceptibility results. Species-level identification and susceptibility testing are essential for optimal disease management and strengthening diagnostic capacity. Keywords: Nontuberculous mycobacteria, Mycobacterium kansasii, Mycobacterium abscessus, antimicrobial susceptibility, pulmonary infection, HIV
- 26 May 2026
- Published by Doc Design and Informatics Co. Ltd. in Infectious Diseases and Clinical Microbiology
- Vol. 8 (3) , 262-272
Open AccessNontuberculosis Mycobacterial Infections: A Series of 14 Cases from a Tertiary Care Center in Türkiye
Objectives: Nontuberculous mycobacteria (NTM) are emerging opportunistic pathogens with an increasing global incidence. However, epidemiological data and treatment outcomes remain limited in Türkiye. This study aimed to evaluate the clinical characteristics, species distribution, and treatment outcomes of NTM infections in a tertiary center in Türkiye. Materials and Methods: A retrospective analysis was conducted of patients diagnosed with NTM infection between 2021 and 2025 in the Department of Infectious Diseases and Clinical Microbiology. The diagnosis was established according to the American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) criteria. Demographic characteristics, risk factors, radiological findings, microbiological profiles, antimicrobial susceptibility patterns, treatment regimens, and clinical outcomes were analyzed. Results: Fourteen patients were included in the study. The mean age was 50.1 ± 13.8 years, and nine patients were male. Underlying risk factors were present in eight patients, including human immunodeficiency virus (HIV) infection (n = 4), malignancy (n = 3), bronchiectasis (n = 1), and chronic obstructive pulmonary disease (COPD) (n = 1). The most frequently identified species were Mycobacterium kansasii (n = 5) and Mycobacterium abscessus (n = 5), followed by Mycobacterium avium, Mycobacterium simiae, Mycobacterium gordonae, and Mycobacterium lentiflavum (n = 1 each). Pulmonary involvement was observed in 10 patients, with nodular lesions in nine and bronchiectasis in five. Among isolates with available antimicrobial susceptibility results (n = 13), susceptibility to clarithromycin, moxifloxacin, linezolid, and amikacin was observed in 12 isolates, whereas resistance was most frequently detected to ciprofloxacin (n = 10) and trimethoprim-sulfamethoxazole (n = 9). Of the 12 patients who initiated treatment, complete clinical response was achieved in nine and partial response in one; two patients with malignancy died before treatment initiation. Conclusion: M. kansasii and M. abscessus were the most frequently identified NTM species in this cohort. Favorable treatment outcomes were observed when therapy was guided by antimicrobial susceptibility results. Species-level identification and susceptibility testing are essential for optimal disease management and strengthening diagnostic capacity. Keywords: Nontuberculous mycobacteria, Mycobacterium kansasii, Mycobacterium abscessus, antimicrobial susceptibility, pulmonary infection, HIV